Equity Profile

BEAM

Beam Therapeutics Inc.

Health CareBiotechnology$3.4B

Mar14Mon

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines using its proprietary base editing technology....

Key Metrics to Watch

Clinical Trial Updates

Investors will be keen to hear about progress in ongoing clinical trials, as successful results could drive stock performance.

Updates on at least one ongoing trial.

Cash Burn Rate

Understanding how much cash the company is using will help investors gauge its financial health and runway until profitability.

Expected to be in line with previous quarters.

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BEAM Q2-2026 Earnings Preview

Context

Company Snapshot

Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines using its proprietary base editing technology. This innovative approach has the potential to treat a variety of genetic diseases, making it a significant player in the health care sector.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+35.03%

Avg Stock Reaction

-2.71%

Last Quarter Recap

In the last quarter, Beam reported an EPS of -$0.91, slightly missing expectations. The stock reacted negatively, dropping 2.69% the following day.

Management Promises & Guidance

Management committed to advancing their clinical trials.
They emphasized the importance of strategic partnerships.
They indicated a focus on managing cash burn effectively.

Expectations

Wall Street Expectations

Overall, expectations are mixed as Beam has shown volatility in its earnings history. Investors are looking for signs of progress in clinical trials and financial stability.

Bull Case

If Beam announces positive clinical trial results or new partnerships, it could significantly boost investor confidence and stock price.

Bear Case

Conversely, if the company reports higher-than-expected cash burn or disappointing trial updates, it could lead to further declines in stock value.

Key Metrics to Watch

Clinical Trial Updates

Updates on at least one ongoing trial.

Investors will be keen to hear about progress in ongoing clinical trials, as successful results could drive stock performance.

Cash Burn Rate

Expected to be in line with previous quarters.

Understanding how much cash the company is using will help investors gauge its financial health and runway until profitability.

Partnership Announcements

At least one new partnership.

Any new collaborations could enhance Beam's research capabilities and market position, which is crucial for future growth.

Expectations

Two Questions That Matter

The print will turn on these two things.

What updates can management provide on the progress of their clinical trials?

Positive updates could indicate the potential for future revenue and growth, which is crucial for investor sentiment.

How is Beam managing its cash burn rate in light of ongoing research and development?

Understanding cash management will help investors assess the company's financial health and sustainability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Beam's potential for positive clinical trial outcomes, which could significantly alter investor sentiment.

Supporting Evidence

The options market is pricing a 10.21% move, indicating expectations of volatility that may not align with historical performance.

Beam's recent partnerships could lead to breakthroughs that have not been fully factored into current valuations.

Key Risk

If the clinical trial updates are more favorable than expected, it could shift the market's perception dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the balance between advancing clinical trials and managing financial resources effectively.

Bull Confirmed If

Positive clinical trial results that exceed expectations could confirm the bull case.

Bear Confirmed If

Higher-than-expected cash burn or negative trial updates would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±10.21%

Historical Avg

±6.2%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±10.2% while BEAM has averaged ±6.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

74.1%

Calls (99K)P/C Ratio: 0.03Puts (3K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Beam beats expectations with positive trial results, history suggests the stock could rise by around 2.09%, confirming bullish sentiment.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may see muted movement as investors digest the information.

Miss

If the company misses expectations, history suggests a potential decline of about 7.50%, which could raise concerns about its future prospects.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the progress of ongoing clinical trials and any preliminary results.
2Updates on cash management strategies and financial projections.
3Any announcements regarding new partnerships or collaborations.
4Insights into the company's long-term strategic vision.
5Management's commentary on market conditions and competitive landscape.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

GitLab Inc.

Company Snapshot

Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines using its proprietary base editing technology....

Key Metrics to Watch

Clinical Trial Updates

Investors will be keen to hear about progress in ongoing clinical trials, as successful results could drive stock performance.

Updates on at least one ongoing trial.

Cash Burn Rate

Understanding how much cash the company is using will help investors gauge its financial health and runway until profitability.

Expected to be in line with previous quarters.

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BEAM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+35.03%

Avg Stock Reaction

-2.71%

Last Quarter Recap

In the last quarter, Beam reported an EPS of -$0.91, slightly missing expectations. The stock reacted negatively, dropping 2.69% the following day.

Management Promises & Guidance

Management committed to advancing their clinical trials.
They emphasized the importance of strategic partnerships.
They indicated a focus on managing cash burn effectively.

Expectations

Wall Street Expectations

Overall, expectations are mixed as Beam has shown volatility in its earnings history. Investors are looking for signs of progress in clinical trials and financial stability.

Bull Case

If Beam announces positive clinical trial results or new partnerships, it could significantly boost investor confidence and stock price.

Bear Case

Conversely, if the company reports higher-than-expected cash burn or disappointing trial updates, it could lead to further declines in stock value.

Key Metrics to Watch

Clinical Trial Updates

Updates on at least one ongoing trial.

Investors will be keen to hear about progress in ongoing clinical trials, as successful results could drive stock performance.

Cash Burn Rate

Expected to be in line with previous quarters.

Understanding how much cash the company is using will help investors gauge its financial health and runway until profitability.

Partnership Announcements

At least one new partnership.

Any new collaborations could enhance Beam's research capabilities and market position, which is crucial for future growth.

Expectations

Two Questions That Matter

The print will turn on these two things.

What updates can management provide on the progress of their clinical trials?

Positive updates could indicate the potential for future revenue and growth, which is crucial for investor sentiment.

How is Beam managing its cash burn rate in light of ongoing research and development?

Understanding cash management will help investors assess the company's financial health and sustainability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Beam's potential for positive clinical trial outcomes, which could significantly alter investor sentiment.

Supporting Evidence

The options market is pricing a 10.21% move, indicating expectations of volatility that may not align with historical performance.

Beam's recent partnerships could lead to breakthroughs that have not been fully factored into current valuations.

Key Risk

If the clinical trial updates are more favorable than expected, it could shift the market's perception dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the balance between advancing clinical trials and managing financial resources effectively.

Bull Confirmed If

Positive clinical trial results that exceed expectations could confirm the bull case.

Bear Confirmed If

Higher-than-expected cash burn or negative trial updates would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±10.21%

Historical Avg

±6.2%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±10.2% while BEAM has averaged ±6.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

74.1%

Calls (99K)P/C Ratio: 0.03Puts (3K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Beam beats expectations with positive trial results, history suggests the stock could rise by around 2.09%, confirming bullish sentiment.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may see muted movement as investors digest the information.

Miss

If the company misses expectations, history suggests a potential decline of about 7.50%, which could raise concerns about its future prospects.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the progress of ongoing clinical trials and any preliminary results.
2Updates on cash management strategies and financial projections.
3Any announcements regarding new partnerships or collaborations.
4Insights into the company's long-term strategic vision.
5Management's commentary on market conditions and competitive landscape.